Key Takeaways & Executive Findings
- •• DILI-Graph, a graph convolutional network with attention, achieves AUC 0.92 for DILI prediction, outperforming baseline methods. • Molecular graph representations capture both local and global structural features, improving predictive accuracy. • Feature importance analysis reveals key substructures (e.g., aromatic rings, halogenated groups) associated with DILI risk. • The model shows strong generalizability on external validation sets, supporting its utility in drug safety screening.
Abstract
Drug-induced liver injury (DILI) is a major cause of acute liver failure and a leading reason for drug attrition during development. Early and accurate prediction of DILI is crucial for drug safety assessment. In this study, we propose a novel deep learning framework, DILI-Graph, that leverages molecular graph representations to predict DILI risk. The model integrates graph convolutional networks (GCNs) with attention mechanisms to capture both local and global structural features of drug molecules. We trained and evaluated DILI-Graph on a comprehensive dataset of 1,200 compounds with well-annotated DILI labels. Our model achieved an area under the receiver operating characteristic curve (AUC) of 0.92, outperforming traditional machine learning methods and existing deep learning approaches. Furthermore, we performed feature importance analysis to identify key molecular substructures associated with DILI, providing interpretable insights. The proposed framework demonstrates robust performance and generalizability across external validation sets. Our findings suggest that molecular graph-based deep learning can significantly enhance DILI prediction, offering a valuable tool for preclinical drug safety screening.
1. Introduction
Drug-induced liver injury (DILI) represents a significant challenge in drug development and clinical practice, accounting for approximately 50% of acute liver failure cases in the United States. The complex mechanisms underlying DILI, including oxidative stress, mitochondrial dysfunction, and immune-mediated responses, make it difficult to predict using conventional approaches. Traditional in vitro and in vivo models are time-consuming and often fail to recapitulate human-specific toxicity. Consequently, there is an urgent need for computational models that can accurately and efficiently assess DILI risk early in the drug discovery pipeline.
Recent advances in deep learning have opened new avenues for toxicity prediction. In particular, graph neural networks (GNNs) have shown promise in learning from molecular graphs, which naturally represent the structure of chemical compounds. Unlike traditional fingerprint-based methods, GNNs can capture the spatial arrangement of atoms and bonds, enabling more nuanced structure-activity relationship modeling. In this study, we introduce DILI-Graph, a GNN-based framework that incorporates attention mechanisms to focus on toxicologically relevant substructures. Our approach aims to improve prediction accuracy and provide interpretable insights into the molecular determinants of DILI.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang, CHEN Yu (2026). Deep Learning-Based Prediction of Drug-Induced Liver Injury Using Molecular Graph Representations. Chinese Traditional and Herbal Drugs. https://doi.org/10.7501/j.issn.0253-2670.2026.6.2026060
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is DILI-Graph?
DILI-Graph is a deep learning framework that uses graph convolutional networks with attention mechanisms to predict drug-induced liver injury (DILI) from molecular structures. It achieves high accuracy (AUC 0.92) and provides interpretable insights into toxic substructures.
How does DILI-Graph compare to traditional methods?
DILI-Graph outperforms traditional machine learning methods (e.g., random forest, SVM) and existing deep learning approaches by leveraging molecular graph representations, which capture both local and global structural features, leading to improved predictive performance.
What data was used to train DILI-Graph?
The model was trained on a comprehensive dataset of 1,200 compounds with well-annotated DILI labels, curated from public databases and literature. External validation sets were used to assess generalizability.
Can DILI-Graph identify toxic substructures?
Yes, through feature importance analysis, DILI-Graph can highlight key molecular substructures, such as aromatic rings and halogenated groups, that are strongly associated with DILI risk, aiding in medicinal chemistry optimization.
What is the practical application of DILI-Graph?
DILI-Graph can be used in preclinical drug safety screening to prioritize compounds with lower DILI risk, thereby reducing attrition rates and improving the efficiency of drug development.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.